Real-World Data & Evidence

Advanced search

The journal “Real-world data & evidence” aims to publish original research and reviews on the use of real-world data (RWD) to assess treatment outcomes and make health decisions. 

Articles published in the journal “Real-world data & evidence” cover, but are not limited, key research areas, such as registers, medical databases, electronic medical records, drug use and outcomes in routine medical practice, drugs prescription, drugs safety, adherence, comparative effectiveness research, pharmacoeconomics and outcomes research, including the cost-of-illness analysis, pragmatic clinical trials, exploring research methodology based on RWD, including collecting, tracking, searching, sharing, analyzing and interpreting Big Data.

Also, the journal website published news about the research carried out in real-world clinical practice, and conferences, congresses and other events announcements.

The journal "Real-world data & evidence" - it is a system of online publications: after the completion of the work on the manuscript, it published on the journal's website as soon as possible with the assignment of a DOI. Once published online, no changes can be made to the manuscript. Every three months, all manuscripts published during this period on the site, combined into a current issue. Before the release of the current issue of the journal, authors can print the articles published on the site, which will contain the necessary output data.

Current issue

Vol 2, No 1 (2022)
View or download the full issue PDF (Russian)


1-9 915

The article provides a brief overview of the main trends in the development of real-world data and real-world evidence (RWD/RWE) paradigm in the United States, Russia, and the Eurasian Economic Union (EAEU) in 2021. The review is compiled in calendar sequence. First, events in the United States are presented, sourced from the information resource, "The Evidence Base". Following this, data for the Russian Federation and the EAEU are collected and stored on the "myRWD — Real Clinical Practice" Facebook page, and in the journal "Real-World Data & Evidence". The information is summarized and a complete picture of the development of real clinical practice and its evidence in the indicated countries is given.


11-16 481

The article describes the regulatory approaches to the collection, analysis and usage of real-world data applied in the European Union and Japan.

17-27 188

The article describes the regulatory approaches to the collection, analysis and usage of real-world data applied in China.


28-35 262

According to a number of studies, medicinal plants and drugs based on them can be used as inhibitors of various viral infections, including the SARS-CoV-2 virus at different stages of their manifestation and development. In a number of countries, official recommendations have been developed for independent and auxiliary therapy of COVID-19 with medicinal plants and drugs based on them. However, in combination with drugs developed for the treatment of COVID-19, various interactions, including adverse ones, may occur.

Purpose: to systematize and analyze data on possible interactions of medicinal plants and natural biologically active substances, which are major active substances in plant raw materials, with medicinal products recommended for the treatment of COVID-19.

Materials and methods. The study selected drugs recommended for the treatment of COVID-19 at various stages and severity with different mechanisms of action. We used open information on confirmed drug interactions on the website of the international database

Results and discussion. The results of possible interactions with the following medicinal plants were revealed: St. John’s wort, Digitalis, Periwinkle, Colchicum, Cinchona, Strophant, Ergot, Pepper, Lemon, Coffee, Tea, Yohimbe tree, Garlic, Evening primrose, Poppy opium, Rauwolfia serpentine.

Conclusion. The drugs used for the treatment of COVID-19 of different anatomical and therapeutic groups are considered, possible changes in their therapeutic efficacy are identified when taken simultaneously with medicinal plants or biologically active substances of plant origin contained in food and nutritional supplements. It is shown that not all interactions may be undesirable. The effect of medicinal plants on the pharmacokinetics of drugs has not been studied enough and seems to be an important and promising aspect of pharmacovigilance activities. Interesting interactions have been identified: St. John’s wort and drugs based on it can cause the induction of CYP3A and reduce the therapeutic effect when used together with drugs: lopinavir, remdesivir, umifenovir, nirmatrelvir; the cardiotoxic effect of interferon can be reduced through the use of medicinal plant materials containing cardiac glycosides; the combination of ferulic acid with peginterferon alfa-2a increases the risk and severity of bleeding. It was found that the Drugbank database does not contain information on drug-drug interactions of medicinal plants with molnupiravir.


36-39 258

Visualization of research results based on data from real clinical practice (RWD) is mandatory when conducting presentations and publishing reports. One of the additional tools that allow you to customize complex reports is the business intelligence service from Microsoft Power BI. The article discusses various ways of loading, processing and visualizing data from clinical registers using the specified software.


40-43 170

Real-world data (RWD) and real-world evidence (RWE) are a valuable resource in the healthcare system. They may be necessary for administrators (to create and improve algorithms for treating patients with various nosologies), physicians (to make a better clinical decision in favor of the patient) and directly to patients and their relatives (to better understand the treatment process). The creators of this data are also the physicians, patients and health care organizations. To process such a volume of data, specialized specialists are needed — mathematicians, data specialists, biostatistics, which in turn generates a service sector in the field of RWD/RWE. Depending on the component, the market is segmented into datasets and services. In 2020, the services segment held a large share — 58.8% of the global RWE solutions market. The market for these services and the data itself is growing every year and is projected to reach 2.3 billion US dollars by 2026.



Experts of Raevsky clinics: oncopsychology is necessary in cancer treatment

On June 30, 2022, an online conference "Treatment of oncology with integrative methods" was held as part of the All-Russian Scientific and Educational Project. It was conducted by the staff of Dmitry Raevsky's network of integrative medicine clinics. They spoke about the need to include oncopsychology in the complex treatment of oncological diseases.


Moscow hosted the 9th annual conference "Health Technology Assessment", dedicated to improving the drug supply strategy

In the new economic conditions, the issue of increasing the efficiency of organizing and financing the healthcare system to ensure the quality and accessibility of medical care both at the federal and regional levels is extremely acute. 



Results of the V Annual All-Russian Scientific and Practical Conference with International Participation "Safety of Pharmacotherapy: Noli nocere!"

On May 19, 2022, the V Annual All-Russian Scientific and Practical Conference with international participation “Safety of Pharmacotherapy: Noli nocere!” was held at the RMANPE, which was held as part of the XIII All-Russian Meeting “Actual Issues of Clinical Pharmacology and Drug Supply”.




On June 21-22, 2022, Moscow will host the IX International Scientific and Practical Conference "Health Technology Assessment: Improving the Strategy for the Development of the Drug Supply System".



Innovative doctors at a free conference will talk about psychotherapy in the treatment of oncology

The free online conference "Psychotherapy in Oncology" will be held on May 26.



Russian Pharmaceutical Forum named after Semashko: the main meeting place for the pharmaceutical market acquires a new name

The Russian Pharmaceutical Forum has been the main platform for meeting the entire Russian pharmaceutical market and discussing the most pressing and pressing issues of the pharmaceutical industry for 28 years. The rich history of the Forum and the challenges that the national drug supply system is currently facing turned the attention of the Forum organizers to the historical experience of building and forming a unique model of the national healthcare system built by the outstanding healthcare organizer Nikolai Semashko.


Overuse of short-acting beta-2-agonists in bronchial asthma in Russia

The international scientific journal Journal of Asthma and Allergy published an article "SABA abuse in Russia - burden and possible causes: analysis of the Russian population included in the SABINA III study", which highlights the results of a study of real clinical practice of Russian patients with bronchial asthma (BA), receiving therapy with SABA (short-acting beta-2-agonists). The study showed that in Russia there is a high level of excessive prescription of SABA, which may be correlated with the problem of inadequate control of the course of bronchial asthma and the occurrence of frequent severe exacerbations. The frequency of SABA overuse was not associated with disease severity.


A systematic review of real-world clinical practice data in COVID-19: non-interventional studies

As defined by the Food and Drug Administration, real-world data (RWD) is data related to a patient's health and/or health care delivery, usually collected from various sources as part of real-world clinical practice research.



The Association of Specialists in the Field of Health Technology Assessment, the Association of Clinical Pharmacologists, the St. Petersburg Division of the International Society for Pharmacoeconomic Research and Scientific Analysis - ISPOR express their deep respect and invite you to accept participation in the work of the III annual scientific and practical RWD / RWE conference: “Real-world data in a changing world. Challenges and Solutions”, which will take place in September 2022, on September 15 or 22.


On April 18-19, the conference "Actual issues of preclinical and clinical trials of drugs and clinical trials of medical devices" will be held

First St. Petersburg State Medical University named after Academician I.P. Pavlov invites you to take part in the IX All-Russian Conference with international participation "Actual issues of preclinical and clinical trials of drugs, biomedical cell products and clinical trials of medical devices", which will be held in St. Petersburg on April 18 and 19, 2022.
More News...

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.